Mоксогамма, Moxogamma (Moxonidine)

Moxonidine selectively stimulates imidazoline I1 receptors in the brainstem, which diminishes sympathetic nervous system activity. This reduction leads to lower peripheral vascular resistance and a decrease in arterial pressure, providing an antihypertensive effect.

The appropriate dose of Mоксогамма is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any comorbid conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for moxonidine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, offering a mechanism distinct from ACE inhibitors, beta‑blockers, or calcium channel blockers. It is particularly useful when sympathetic overactivity contributes to hypertension, and it may be combined with other classes for additive blood‑pressure control.

Store Mоксогамма tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

Mоксогамма is taken orally, usually once daily, with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse reactions, although rare, include severe hypotension, bradycardia, allergic responses such as rash or angioedema, hepatic dysfunction, and renal impairment. Patients should seek immediate medical attention if they experience any of these symptoms.

Mоксогамма is contraindicated in patients with known hypersensitivity to moxonidine or any tablet excipients. Caution is advised for individuals with severe hepatic or renal disease, and it should be avoided in patients where excessive blood‑pressure reduction could be hazardous.